Research programme: RNA modifying enzymes inhibitors - Storm Therapeutics
Latest Information Update: 28 Jun 2026
At a glance
- Originator Storm Therapeutics
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action ADAR protein inhibitors; RNA modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Coronavirus infections
Most Recent Events
- 28 Jun 2026 No recent reports of development identified for research development in Coronavirus-infections in United Kingdom
- 28 Nov 2025 No recent reports of development identified for research development in Cancer in United Kingdom
- 03 May 2022 Early research in Coronavirus infections in United Kingdom (unspecified route), prior to May 2022